Benjamin Bader
Overview
Explore the profile of Benjamin Bader including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
776
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Graham K, Lienau P, Bader B, Prechtl S, Naujoks J, Lesche R, et al.
Cell Chem Biol
. 2024 Mar;
31(7):1247-1263.e16.
PMID: 38537632
This study describes the identification and target deconvolution of small molecule inhibitors of oncogenic Yes-associated protein (YAP1)/TAZ activity with potent anti-tumor activity in vivo. A high-throughput screen (HTS) of 3.8...
2.
Kober C, Roewe J, Schmees N, Roese L, Roehn U, Bader B, et al.
J Immunother Cancer
. 2023 Nov;
11(11).
PMID: 37963637
Background: The metabolism of tryptophan to kynurenines (KYN) by indoleamine-2,3-dioxygenase or tryptophan-2,3-dioxygenase is a key pathway of constitutive and adaptive tumor immune resistance. The immunosuppressive effects of KYN in the...
3.
Zablowsky N, Farack L, Rofall S, Kramer J, Meyer H, Nguyen D, et al.
Noncoding RNA
. 2023 Jan;
9(1).
PMID: 36649031
Traditionally, small molecule-based drug discovery has mainly focused on proteins as the drug target. Opening RNA as an additional target space for small molecules offers the possibility to therapeutically modulate...
4.
Hillig R, Bader B
Adv Cancer Res
. 2022 Feb;
153:169-203.
PMID: 35101230
RAS proteins play major roles in many human cancers, but programs to develop direct RAS inhibitors so far have only been successful for the oncogenic KRAS mutant G12C. As an...
5.
Berger M, Wortmann L, Buchgraber P, Lucking U, Zitzmann-Kolbe S, Wengner A, et al.
J Med Chem
. 2021 Aug;
64(17):12723-12737.
PMID: 34428039
Eukaryotes have evolved two major pathways to repair potentially lethal DNA double-strand breaks. Homologous recombination represents a precise, DNA-template-based mechanism available during the S and G2 cell cycle phase, whereas...
6.
Lemos C, Schulze V, Baumgart S, Nevedomskaya E, Heinrich T, Lefranc J, et al.
Cell Oncol (Dordr)
. 2021 Jan;
44(3):581-594.
PMID: 33492659
Purpose: 5' adenosine monophosphate-activated kinase (AMPK) is an essential regulator of cellular energy homeostasis and has been associated with different pathologies, including cancer. Precisely defining the biological role of AMPK...
7.
Lucking U, Wortmann L, Wengner A, Lefranc J, Lienau P, Briem H, et al.
J Med Chem
. 2020 Jun;
63(13):7293-7325.
PMID: 32502336
The ATR kinase plays a key role in the DNA damage response by activating essential signaling pathways of DNA damage repair, especially in response to replication stress. Because DNA damage...
8.
Schulze V, Klar U, Kosemund D, Wengner A, Siemeister G, Stockigt D, et al.
J Med Chem
. 2020 Apr;
63(15):8025-8042.
PMID: 32338514
Inhibition of monopolar spindle 1 (MPS1) kinase represents a novel approach to cancer treatment: instead of arresting the cell cycle in tumor cells, cells are driven into mitosis irrespective of...
9.
Mortier J, Friberg A, Badock V, Moosmayer D, Schroeder J, Steigemann P, et al.
ChemMedChem
. 2020 Apr;
15(10):827-832.
PMID: 32237114
Due to its frequent mutations in multiple lethal cancers, KRAS is one of the most-studied anticancer targets nowadays. Since the discovery of the druggable allosteric binding site containing a G12C...
10.
Lefranc J, Schulze V, Hillig R, Briem H, Prinz F, Mengel A, et al.
J Med Chem
. 2019 Dec;
63(2):601-612.
PMID: 31859507
The serine/threonine kinase TBK1 (TANK-binding kinase 1) and its homologue IKKε are noncanonical members of the inhibitor of the nuclear factor κB (IκB) kinase family. These kinases play important roles...